Journal
CANCER MEDICINE
Volume 12, Issue 3, Pages 2918-2928Publisher
WILEY
DOI: 10.1002/cam4.5206
Keywords
anamorelin; appetite; body weight; cancer cachexia; lean body mass; non-small cell lung cancer
Categories
Ask authors/readers for more resources
This study investigated the efficacy and safety of anamorelin in subgroups of Japanese NSCLC patients. The results showed significant improvements in lean body mass, body weight, and appetite in most patients, with good tolerability.
Background Cachexia, a disorder associated with anorexia, inflammation, and muscle wasting, is frequent in cancer patients. We performed post-hoc analyses of the ONO-7643-04 study to investigate the efficacy and safety of anamorelin in subgroups of Japanese patients with non-small cell lung cancer (NSCLC). Methods The patients were divided into subgroups by baseline characteristics, including sex, age, body mass index, prior weight loss, performance status (PS), concomitant anticancer therapy, and number of previous chemotherapy regimens. The changes from baseline through to 12 weeks for lean body mass (LBM), body weight, and appetite were calculated. Appetite was evaluated using the quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD) item 8 score. Responder rates were defined as the maintenance/improvement of LBM (>= 0 kg), body weight (>= 0 kg), or QOL-ACD item 8 score (>= 0) from baseline to all evaluation time points. Safety was evaluated in patients subgrouped by age and PS. Results Anamorelin resulted in greater improvements versus placebo in LBM, body weight, and appetite in most subgroups. Anamorelin was also associated with greater LBM, body weight, and appetite responder rates than placebo in nearly all subgroups. Among anamorelin-treated patients, adverse drug reactions (ADRs) tended to be more frequent with increasing age (<65 years, 19.2%; >= 65 to <75 years, 45.9%; >= 75 years, 60.0%) and PS score (PS 0-1, 38.4%; PS 2, 60.0%). The frequency of serious ADRs was 2.7% and 0% in the PS 0-1 and PS 2 subgroups, respectively. Conclusion This study of NSCLC patients with cancer cachexia revealed consistent improvements in LBM, body weight, and appetite across most subgroups of anamorelin-treated patients. This study also demonstrated the tolerability of anamorelin regardless of age and PS, with a low incidence of serious ADRs in each subgroup.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available